Yue Hsin Lin
Founder chez LIN BIOSCIENCE, INC.
Fortune : 78 M $ au 31/03/2024
Profil
Yue Hsin Lin is the founder and currently holds the position of Chairman, General Manager & Spokesman at Lin BioScience, Inc. which was founded in 2016.
He is also the founder and currently serves as Chairman & Chief Executive Officer at Belite Bio, Inc. which was founded in 2018.
Dr. Lin's current job positions include Chief Executive Officer & Director at RBP4 Pty Ltd.
since 2018, Chairman, President & Chief Executive Officer at Belite Bio Holdings Corp.
since 2016, Director at Belite Bio (HK) Ltd.
since 2021, and President at Belite Bio LLC since 2021.
Dr. Lin's former job positions include Senior Director-Medical at OBI Pharma, Inc. from 2010 to 2014, Medical Director & General Manager at Aslan Pharmaceuticals Ltd., and President & Chief Operating Officer at CVie Therapeutics Ltd.
from 2014 to 2016.
Dr. Lin's education history includes an MBA from The Trustees of Columbia University in The City of New York, an undergraduate degree from the University of Pennsylvania, an MBA from the University of Hong Kong, a doctorate degree from The University of Sydney, and an MBA from London Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BELITE BIO, INC.
8,12% | 31/12/2023 | 2 022 546 ( 8,12% ) | 78 M $ | 31/03/2024 |
Postes actifs de Yue Hsin Lin
| Sociétés | Poste | Début |
|---|---|---|
| LIN BIOSCIENCE, INC. | Founder | 12/05/2016 |
| BELITE BIO, INC | Chief Executive Officer | 27/03/2018 |
Belite Bio LLC
 Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The private company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | President | 01/10/2021 |
| RBP4 Pty Ltd. | Chief Executive Officer | 01/04/2021 |
| Belite Bio Holdings Corp. | Chief Executive Officer | 01/12/2017 |
| Belite Bio (HK) Ltd. | Director/Board Member | 01/06/2021 |
Anciens postes connus de Yue Hsin Lin
| Sociétés | Poste | Fin |
|---|---|---|
CVie Therapeutics Ltd.
 CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The private company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | President | 01/01/2016 |
| OBI PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01/01/2014 |
| ASLAN PHARMACEUTICALS LIMITED | Chief Tech/Sci/R&D Officer | - |
Formation de Yue Hsin Lin
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| University of Pennsylvania | Undergraduate Degree |
| University of Hong Kong | Masters Business Admin |
| The University of Sydney | Doctorate Degree |
| London Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| OBI PHARMA, INC. | Health Technology |
| ASLAN PHARMACEUTICALS LIMITED | Health Technology |
| LIN BIOSCIENCE, INC. | Health Technology |
| BELITE BIO, INC | Health Technology |
| Entreprise privées | 5 |
|---|---|
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The private company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | Health Technology |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The private company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Health Technology |
| RBP4 Pty Ltd. | |
| Belite Bio Holdings Corp. | |
| Belite Bio (HK) Ltd. |
